WHO to help bring cheap biosimilar cancer drugs to poor

WHO also plans to explore options for insulin

The World Health Organization (WHO) is to launch a pilot project this year to assess cheap copies of expensive biotech cancer drugs in a bid to make such medicines more widely available in poorer countries.

The U.N. agency said it would invite drugmakers in September to submit applications for prequalification of so-called biosimilar versions of two such drugs on its essential medicines list, Roche's Rituxan and Herceptin.

WHO also plans to explore options for prequalifying biosimilar insulin.

The move is a boost for biosimilars which are expected to account for a growing proportion of treatments, particularly for cancer, as patents on the original branded products expire.

The WHO plays a critical role in monitoring drug quality in poorer countries through its prequalification program, which ensures that treatments supplied by U.N. agencies such as UNICEF are of acceptable quality.

The program is also used by many governments to guide the bulk purchase of medicines.

"Innovator biotherapeutic products are often too expensive for many countries, so biosimilars are a good opportunity to expand access and support countries to regulate and use these medicines," said WHO Assistant Director General Marie-Paule Kieny.

Roche's Rituxan, known generically as rituximab, is used principally to treat blood cancers, while Herceptin, or trastuzumab, is a treatment for breast cancer.

The complex nature of biological medicines, which are made inside living cells, means copies can never be exactly the same as the original. But a growing number of such drugs have been approved as similar enough to do the job in several markets.

Ahram Online welcomes readers' comments on all issues covered by the site, along with any criticisms and/or corrections. Readers are asked to limit their feedback to a maximum of 1000 characters (roughly 200 words). All comments/criticisms will, however, be subject to the following code

We will not publish comments which contain rude or abusive language, libelous statements,
slander and personal attacks against any person/s.

We will not publish comments which contain racist remarks or any kind of racial
or religious incitement against any group of people, in Egypt or outside it.

We welcome criticism of our reports and articles but we will not publish personal
attacks, slander or fabrications directed against our reporters and contributing
writers.

We reserve the right to correct, when at all possible, obvious errors in spelling
and grammar. However, due to time and staffing constraints such corrections will
not be made across the board or on a regular basis.